研究者詳細 - 中村　圭一郎

論文 - 中村　圭一郎

分割表示 205 件中 141 - 160 件目／全件表示 >>

治療前サルコペニアは子宮頸癌の予後を反映しない

松岡敬典, 中村圭一郎, 松原侑子, 依田尚之, 西條昌之, 西田傑, 小川千加子, 増山寿

日本婦人科腫瘍学会雑誌 37 ( 3 ) 477 - 477 2019年6月

当院の子宮頸癌症例におけるFIGO2018分類での検討

松原侑子, 中村圭一郎, 松岡敬典, 西條昌之, 依田尚之, 西田傑, 小川千加子, 増山寿

日本婦人科腫瘍学会雑誌 37 ( 3 ) 443 - 443 2019年6月

子宮全摘子宮頸癌放射線治療後残存に対するSalvage Surgeryの8例

小川千加子, 松原侑子, 松岡敬典, 依田尚之, 西田傑, 中村圭一郎, 増山寿

日本婦人科腫瘍学会雑誌 37 ( 3 ) 475 - 475 2019年6月

Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy. 国際誌

Hirofumi Matsuoka, Keiichiro Nakamura, Yuko Matsubara, Naoyuki Ida, Takeshi Nishida, Chikako Ogawa, Kuniaki Katsi, Susumu Kanazawa, Hisashi Masuyama

Anticancer research 39 ( 2 ) 933 - 939 2019年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND/AIM: The objective of this study was to determine if sarcopenia was a predictor of poor prognosis in patients with cervical cancer (CC) undergoing concurrent chemoradiation therapy (CCRT) or radiation therapy (RT). MATERIALS AND METHODS: A total of 236 patients with CC undergoing CCRT or RT were retrospectively examined. We determined if clinical characteristics and survival were correlated with pretreatment sarcopenia, measured as psoas muscle index (PI) or skeletal muscle index (SMI). RESULTS: Pretreatment PI and SMI were related to parametrial involvement with CC undergoing CCRT or RT (p=0.002, and, p=0.034, respectively). The median progression-free survival (PFS) and overall survival (OS) times in patients undergoing CCRT or RT were 29.0 and 34.5 months, respectively. Neither PI nor SMI were prognostic predictors in patients with CC undergoing CCRT or RT. CONCLUSION: Sarcopenia is not a predictive factor of outcome in patients with CC undergoing CCRT or RT.

DOI： 10.21873/anticanres.13196

PubMed

researchmap

上皮性卵巣癌患者の筋肉量と予後予測について

松原侑子, 中村圭一郎, 松岡敬典, 西條昌之, 依田尚之, 西田傑, 小川千加子, 増山寿

日本産科婦人科学会雑誌 71 ( 臨増 ) S - 604 2019年2月

腹腔鏡下両側付属器切除後に判明した正常大卵巣の明細胞境界悪性腫瘍の一例

片山沙希, 久保光太郎, 松岡敬典, 依田尚之, 西田傑, 小川千加子, 中村圭一郎, 増山寿

日本産科婦人科学会雑誌 71 ( 臨増 ) S - 625 2019年2月

異なる転帰をたどった成熟嚢胞性奇形腫を伴う抗NMDA受容体抗体脳炎の2症例

西田傑, 松原侑子, 依田尚之, 松岡敬典, 西條昌之, 小川千加子, 中村圭一郎, 増山寿

日本産科婦人科学会雑誌 71 ( 臨増 ) S - 527 2019年2月

リアルタイムCGMを用いた陣痛発来後から産褥早期までの血糖動態の検討

牧尉太, 衛藤英理子, 中村圭一郎, 平松祐司, 増山寿

糖尿病と妊娠 18 ( 3 ) S - 92 2018年11月

婦人科がんサバイバーは健康的な生活を心掛けている

中村圭一郎, 松岡敬典, 牧尉太, 西條昌之, 依田尚之, 増山寿

日本女性医学学会雑誌 26 ( Suppl. ) 237 - 237 2018年10月

婦人科がんサバイバーは健康的な生活を心掛けているライフスタイル変化についてのアンケート調査結果より

中村圭一郎, 原賀順子, 西田傑, 依田尚之, 西條昌之, 小川千加子, 楠本知行, 増山寿

日本婦人科腫瘍学会雑誌 36 ( 4 ) 692 - 701 2018年10月

記述言語：日本語出版者・発行元：(公社)日本婦人科腫瘍学会

婦人科癌は治療法の進歩によりがんサバイバーが増え、がんサバイバーにとって、再発や死亡を防ぐことが重要である。がん治療終了後生活は生活習慣(食事、喫煙、飲酒)、運動などに注意することが大切とされているが、未だ婦人科領域におけるがん治療終了後生活の現状は把握されていない。そこでがん治療を行った229名の婦人科癌患者を対象に16項目のアンケートを用い、がん治療後の生活実態を調査した。定期的な外来検診を行った健康的な婦人科癌患者に直接アンケートを配布し、ボックスにて回収を行った(99.9%回収)。その結果、がん治療後食事量が減少した患者は24.0%、脂肪摂取が減った患者は34.9%、塩分量が減少した患者は24.9%、緑黄色野菜が増えた患者は47.2%であり、禁煙や喫煙減少した患者は59.2%、禁酒や飲酒量減少した患者は46.8%を占めており、がん治療終了後健康的な生活を送ることに多くのがんサバイバーが心掛けていることを認識できた。(著者抄録)

researchmap

The Influence of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life of Gynecologic Cancer Survivors. 国際誌

Hirofumi Matsuoka, Keiichiro Nakamura, Yuko Matsubara, Naoyuki Ida, Masayuki Saijo, Chikako Ogawa, Hisashi Masuyama

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 28 ( 7 ) 1394 - 1402 2018年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

OBJECTIVE: The aim of this observational study was to investigate correlations between long-term chemotherapy-induced peripheral neurotoxicity (CIPN) and quality of life (physical well-being, social well-being, emotional well-being, and functional well-being [FWB]) among survivors of gynecologic cancer (GC). METHODS: We aimed to assess the correlation of quality of life and long-term CIPN with the temporal change in recurrence-free GC survival. Questionnaire responses and clinical data of 259 GC survivors were collected and assessed according to treatment received. The χ test was used to determine the significance of correlations. RESULTS: Of 165 evaluable patients treated by chemotherapy, 36 patients (21.8%) developed CIPN of Common Toxicity Criteria for Adverse Events grade 1 or higher during the study. Chemotherapy-induced peripheral neurotoxicity had significantly improved over time in the domain of FWB at 61 months or more after the end of chemotherapy (posttreatment 4) among GC survivors (P = 0.003). Furthermore, CIPN treated by more than 6 courses of the paclitaxel and carboplatin regimen among GC survivors showed significant improvement over time in the emotional well-being domain at 25 to 60 months and 61 months or more after the end of chemotherapy (posttreatments 3 and 4) (P = 0.037 and P = 0.023) and in FWB at posttreatment 4 (P < 0.001). CONCLUSIONS: Emotional and functional domains of CIPN improved over time among GC survivors treated by more than 6 courses of the paclitaxel and carboplatin regimen. Based on these results, further research is required to identify additional preventative or curative approaches.

DOI： 10.1097/IGC.0000000000001320

PubMed

researchmap

Lynch症候群子宮体癌におけるMMR statusとLynch症候群関連腫瘍家族歴との相関

原賀順子, 永坂岳司, 春間朋子, 西田傑, 入谷大洋, 母里淑子, 小川千加子, 中村圭一郎, 藤原俊義, 増山寿

日本外科系連合学会誌 43 ( 3 ) 401 - 401 2018年5月

Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles. 国際誌

Yoshiko Mori, Akihiro Nyuya, Kazuya Yasui, Toshiaki Toshima, Takashi Kawai, Fumitaka Taniguchi, Keisuke Kimura, Ryo Inada, Masahiko Nishizaki, Junko Haraga, Keiichiro Nakamura, Yuzo Umeda, Hiroyuki Kishimoto, Toshiyoshi Fujiwara, Yosuke Katata, Yoshiyuki Yamaguchi, Takeshi Nagasaka

Oncotarget 9 ( 23 ) 16477 - 16488 2018年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

We clarified the clinical prevalence of ovarian metastases from colorectal cancers (CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability (MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian metastases [6.4% (n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-ovarian metastases only [32.4% (n = 96), 5-year OS = 34.5%] and CRCs without any recurrence or metastasis [61.2% (n = 181), 5-year OS = 91.3%]. All patients with ovarian metastases underwent oophorectomy; of these, 9 who received preoperative chemotherapy had measurable metastases to extra-ovarian sites and the ovaries. Although 5 of 9 (56%) achieved partial response or complete response at extra-ovarian sites, no patient archived objective response at ovarian sites. Regarding the mutation profiles, in CRCs with extra-ovarian metastases only, the median survival time (MST) after initial treatments to progression to stage IV or recurrence was 13 [95% confidence interval (CI): 7-16 months] in BRAF-mutant and 34 months (95% CI: 22-58 months) in BRAF wild-type (P = 0.0033). Although ovarian metastases demonstrated poor response to systemic chemotherapy in CRCs with ovarian metastases, the MST after initial treatments to progression to stage IV or recurrence was 22 (95% CI: 21-25 months) in BRAF-mutant and 38 months (95% CI: 24-42 months) in BRAF wild-type (P = 0.0398). The outcomes of patients with ovarian metastases could be improved by oophorectomy regardless of their mutation profiles.

DOI： 10.18632/oncotarget.24735

PubMed

researchmap

Prognostic nutritional index as a predictor of survival in patients with recurrent cervical cancer. 国際誌

Naoyuki Ida, Keiichiro Nakamura, Masayuki Saijo, Tomoyuki Kusumoto, Hisashi Masuyama

Molecular and clinical oncology 8 ( 2 ) 257 - 263 2018年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Systemic inflammatory responses (SIRs) can help predict survival in various cancers. The present study investigated the accuracy of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and prognostic nutritional index (PNI) in predicting survival for patients with recurrent cervical cancer. A retrospective review of prognoses examined the associations among NLR, PLR, and PNI, and clinical characteristics and survival in 79 patients with recurrent cervical cancer after undergoing concurrent chemoradiation therapy (CCRT) or radical hysterectomies with or without CCRT. The Mann-Whitney U-test was used for statistical analyses. In addition, 12-month, 24-month and overall survival were analyzed by the Kaplan-Meier method. Cox's proportional hazard regression was used for univariate and multivariate analyses. Median survival was 15.0 months over follow-up periods of 2-93 months. At the last follow-up point, 54 had succumbed to disease and 25 were alive with disease. In univariate analysis, NLR, PLR and PNI were significantly associated with 12-month, 24 month and overall survival (12 months: P=0.021, P=0.001 and P<0.001; 24 months: P=0.020, P=0.008 and P<0.001; overall; P=0.032, P=0.032 and P<0.001, respectively). In multivariate analyses, PNI was an independent prognostic factor for 12-month, 24-month and overall survival (P=0.001, P=0.001 and P<0.001, respectively). PNI is a useful predictor of survival of recurrent cervical cancer.

DOI： 10.3892/mco.2017.1508

PubMed

researchmap

再発リスクを有する子宮体癌において,POLE変異/MSIは予後良好因子である

原賀順子, 永坂岳司, 春間朋子, 西田傑, 中村圭一郎, 増山寿

日本産科婦人科学会雑誌 70 ( 2 ) 646 - 646 2018年2月